A mathematical investigation of the multiple pathways to recurrent prostate cancer: Comparison with experimental data

Neoplasia

Volumn 6, Issue 6, 2004, Pages 697-704

  Jackson, Trachette L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Androgen independent relapse; LNCaP; LuCap; Mathematical model; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; HORMONE; PROTEIN BCL 2;

ANDROGEN DEPRIVATION THERAPY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RESISTANCE; COMPARATIVE STUDY; EXPERIMENT; HUMAN; LNCAP TUMOR XENOGRAFT; LUCAP TUMOR XENOGRAFT; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR UPREGULATION; SIMULATION; TUMOR XENOGRAFT;

EID: 11144352221     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04259     Document Type: Article

References (24)

1. Greenlee RT, Murray T, Bolden S, and Wingo PA (2000). Cancer statistics 2000. CA Cancer J Clin 50, 7-33.
2. Crawford ED, Rosenblum M, Ziada AM, and Lange PH (1999). Hormone refractory prostate cancer. Urology 54 (Suppl 6A), 1-7.
3. Denis LJ and Griffiths K (2000). Endocrine treatment in prostate cancer. Semin Surg Oncol 18, 52-74.
4. Palmberg C, Koivisto P, Kakkola L, Tammela TLJ, Kallioniemi OP, and Visakorpi T (2000). Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate. J Urol 164 (6), 1992-1995.
5. Basaria S, Leib J, Tang AM, DeWeese T, Carducci M, Eisenberger M, and Dobs AS (2002). Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 56 (6), 779-786.
6. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, and Lin MF (2002). Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 50 (4), 222-235.
7. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, and Isaacs JT (1995). Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1, 473-480.
8. Rini BI and Small EJ (2002). Prostate cancer update. Curr Opin Oncol 14 (3), 286-291.
9. Gregory CW, Johnson RT, Presnell SC, Mohler JL, and French F (2001b). Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft. J Androl 22 (4), 537-548.
10. Nelson WG, De Marzo AM, and Isaacs WB (2003). Prostate cancer. N Engl J Med 349 (4), 366-381.
11. Litvinov IV, De Marzo AM, and Isaacs JT (2003). Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 88 (7), 2972-2982.
12. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, and Sawyers CL (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (1), 33-39.
13. + cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer 65, 85-89.
14. Ellis WJ, Vessella RL, Buhler KR, Bladou F, True LD, Bigler SA, Curtis D, and Lange PH (1996). Characterization of a novel androgen-sensitive prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 2, 1039-1048.
15. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, and Wilson EM (2004). Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 279, 7119-7130.
16. Bladou F, Vessella RL, Buhler KR, Ellis WJ, True LD, and Lange PH (1996). Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int J Cancer 67, 785-790.
17. Greenspan HP (1976). On the growth and stability of cell cultures and solid tumors. J Theor Biol 56, 229-235.
18. Byrne HM and Chaplain MAJ (1996). Modelling the role of cell-cell adhesion in the growth and development of carcinoma. Math Comput Model 24 (12), 1-17.
19. Jackson TL and Byrne HM (2000). A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. Math Biosci 164 (1), 17-38.
20. Jackson TL (2002). Vascular tumor growth and treatment: consequences of polyclonality, competition, and dynamic vascular support. J Math Biol 44, 201-226.
21. Woodward DE, Cook J, Tracqui P, Cruywagen GC, Murray JD, and Alvord EC (1996). A mathematical model of glioma growth: the effect of extent of surgical resection. Cell Prolif 29, 269-288.
22. Burgess PK, Kulesa PM, Murray JD, and Alvord EC (1997). The interaction of growth rates and diffusion coefficients in a three-dimensional mathematical model of gliomas. J Neuropathol Exp Neurol 56, 704-713.
23. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, and Wilson EM (2001). A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61 (11), 4315-4319.
24. Bray D (2001). Cell Movements Garland Publishing, New York, NY.